Welcome to our dedicated page for CytoMed Therapeutics news (Ticker: GDTC), a resource for investors and traders seeking the latest updates and insights on CytoMed Therapeutics stock.
CytoMed Therapeutics Limited (NASDAQ: GDTC) is a Singapore-based clinical stage biopharmaceutical company developing donor-derived, cell-based allogeneic immunotherapies for cancers. This news page aggregates company announcements, clinical updates and regulatory disclosures so readers can follow how CytoMed’s gamma delta T cell and iPSC-derived platforms progress from research into clinical application.
According to its public communications, CytoMed is advancing a Phase I CAR gamma delta T cell trial in Singapore (the ANGELICA Trial), supporting a Phase II Investigator-Initiated Trial in India, and preparing a first-in-human trial in Malaysia for unmodified allogeneic γδ T cells in collaboration with Universiti Malaya. News items frequently cover milestones such as completion of dose levels in the ANGELICA Trial, memoranda of understanding with hospital partners, and publications of collaborative research with institutions like The University of Texas MD Anderson Cancer Center on donor-derived Vγ9Vδ2 T cells for acute myeloid leukemia.
Investors and observers can also find updates on CytoMed’s corporate developments, including the build-out of its cord blood-derived platform under subsidiary LongevityBank, the acquisition of a licensed cord blood bank in Malaysia, and non-dilutive investment into LongevityBank. Additional announcements may describe asset acquisitions related to T cell technologies, at-the-market equity programs, and changes in significant shareholdings.
For those tracking GDTC, this news feed provides a centralized view of CytoMed’s progress in oncology-focused cell therapies, its expansion into cord blood-derived and regenerative applications, and its evolving strategy in Southeast Asia, India and China. Regularly reviewing these updates can help readers understand how the company’s clinical, scientific and corporate activities develop over time.
CytoMed Therapeutics (NASDAQ: GDTC) issued a statement on January 28, 2026, rejecting inaccurate public claims about its research, clinical progress, and operations. The company confirmed its lead CAR γδ T cell program received regulatory approval for a first-in-human trial, currently ongoing at National University Hospital, Singapore.
CytoMed said other candidates, including iPSC-derived γδ NKT therapies, remain in preclinical development and that no product is approved for commercial use.
CytoMed Therapeutics (NASDAQ: GDTC) provided a 2026 update outlining clinical and corporate progress. The company is developing donor-derived gamma delta T cell therapies and advancing Natural Killer (NK) cell process development via subsidiary LongevityBank, with support from Enterprise Singapore. CytoMed says it has resources to fund operations for at least one year and may monetise real estate or pursue licensing/partnerships to reduce dilution. Key clinical items: a MoU with Universiti Malaya for a multi-site Phase I CTM-GDT trial in Malaysia with an IND targeted before June 2026, and an ongoing Phase I CAR T trial in Singapore with six patients treated. The company co-authored a Sept/Oct 2025 preclinical paper with MD Anderson. Chairman Peter Choo intends to increase his shareholding and the company seeks shareholder feedback on a proposal linking shareholding to patient access to therapies.
CytoMed Therapeutics (NASDAQ: GDTC) on December 8, 2025 announced a Memorandum of Understanding with Universiti Malaya Medical Centre to establish a multi-site, first-in-human Phase I clinical trial in Malaysia to test its donor-derived unmodified gamma delta (γδ) T cells (CTM-GDT) for patients with limited treatment options. This program complements CytoMed’s ongoing Phase I CAR T trial in Singapore using engineered γδ T cells (CTM-N2D). CytoMed is co-author of a September 2025 research article reporting promising preclinical/early results for donor-derived Vγ9Vδ2 T cells in acute myeloid leukemia, supporting further clinical study.
The collaboration aims to evaluate safety and efficacy of allogeneic off-the-shelf γδ T cells and to expand access to affordable immunotherapy in Southeast Asia.
CytoMed Therapeutics (NASDAQ: GDTC) secured a non-dilutive investment into its subsidiary LongevityBank from ICH Capital, with ICH Capital agreeing to invest up to US$500,000 for a 10.0% post-money stake in LongevityBank.
CytoMed will concentrate on donor-derived allogeneic cell therapies (IND Phase I ongoing in Singapore; Phase II IIT in India), while LongevityBank will focus on autologous cell banking and therapies. CytoMed said CNIPA granted patents for its gamma delta and CAR-γδ technologies, and cited China State Council Decree No. 818 (Oct 10, 2025) as a new regulatory pathway to clinical application for cell therapies.
CytoMed Therapeutics (NASDAQ: GDTC) announced on October 22, 2025 that Executive Chairman Peter Choo purchased an additional 105,824 shares in open-market trades, raising his personal holding to 187,500 shares (2.50%).
He also holds shares through related entities — Glorious Finance Limited (55% owner) and sole ownership of EP Capital Inc — which together represent 2,282,422 shares (19.45%). In aggregate he controls 2,388,246 shares, or 21.95% of outstanding shares. The company said it will update on any further purchases and advised investors to exercise caution when trading until further announcements.
CytoMed (NASDAQ: GDTC) submitted a cash bid on Oct 14, 2025 to acquire relevant assets of TC BioPharm Limited (TCBL) from joint administrators Michael Magnay and Rob Croxen, who were appointed on Oct 2, 2025. TCBL has completed a Phase I trial; CytoMed is conducting the Phase I ANGELICA trial in Singapore under an IND evaluating proprietary CAR T cells. The Proposed Acquisition aims to deepen CytoMed’s expertise in donor-derived gamma delta T cells, accelerate commercialization, and leverage Southeast Asia cost structures. Funding is planned from internal resources. More details, including transaction terms, will be announced when available; investors are advised to exercise caution.
CytoMed Therapeutics (NASDAQ:GDTC) announced the publication of a preclinical study conducted in collaboration with MD Anderson Cancer Center, focusing on donor-derived γδ T cells for treating acute myeloid leukemia (AML). The research demonstrates promising potential for CytoMed's allogeneic γδ T cell therapy (CTM-GDT).
The study supports the company's advancement of γδ T cell-based treatments, following their leading product CAR-γδ T cells (CTM-N2D) which is currently in Phase 1 clinical trials in Singapore. CytoMed plans to expand clinical trials across Southeast Asia to provide novel immunotherapy options for patients with limited treatment alternatives.
CytoMed Therapeutics (NASDAQ: GDTC) has announced significant developments following its October 2024 acquisition of a Malaysian cord blood bank. The company has successfully expanded clinical-scale NK cells from decade-old cryopreserved cord blood units and is reorganizing its structure through LongevityBank, which owns the licensed cord blood bank IPSC Depository.
The company is pursuing a dual-strategy approach: CytoMed will focus on donor blood-derived allogeneic therapies (currently in Phase I and Phase II trials), while LongevityBank will concentrate on autologous therapies. Management and EP Capital Inc plan to invest up to $500,000 in LongevityBank's equity at double the acquisition valuation. The company intends to eventually spinoff LongevityBank as a standalone cord blood-based biopharmaceutical company.
CytoMed Therapeutics (NASDAQ: GDTC), a Singapore-based clinical stage biopharmaceutical company, has announced an At-the-Market (ATM) offering program to raise up to $4.3 million through R.F. Lafferty & Co. as sales agent.
The company will determine the timing and amount of share sales based on market conditions and capital needs. Proceeds will support general corporate purposes, business development initiatives, capital expenditures, and potential strategic acquisitions. Additionally, CytoMed reported that its recently acquired cord blood bank has attracted 2,500 new customers since its acquisition in August 2024, contributing to 2025 revenue.
CytoMed Therapeutics (NASDAQ: GDTC) has successfully completed dose level 1 of its ANGELICA Trial, a Phase I dose-escalation clinical study evaluating CTM-N2D in late-stage cancer patients. The company plans to proceed with dose level 2 in Q3 2025.
The trial focuses on CTM-N2D, an innovative allogeneic NKG2DL-targeting CAR gamma delta T cell therapy designed to treat advanced solid tumors and blood cancers. Unlike traditional CAR-T therapies, CTM-N2D uses donor-derived cells that don't require patient matching, potentially offering a more accessible treatment option. The therapy targets NKG2DL, proteins commonly found in various cancers, providing a potentially broader application compared to conventional treatments.